Angle Plc Surrey Stock Price, News & Analysis

CelLBxHealth plc (OTC:ANPCF) announced board changes effective immediately on 12 January 2026. Peter Collins was appointed Chief Executive Officer and Klaas de Boer, Kim Oreskovic and Benjamin Hart were appointed as Non-Executive Directors. Separately, Non-Executive Director Joseph Eid will step down from the board, effective 31 January 2026. The announcement states required AIM Rule 17 and Schedule 2(g) information is provided and that the disclosure is deemed inside information under the EU Market Abuse Regulation.

Cellbxhealth (OTC:ANPCF) disclosed a major holding notification: Conifer Management, L.L.C. crossed a threshold on 18-Dec-2025 and was notified to the issuer on 22-Dec-2025. The resulting situation shows Conifer holds 29.900% of voting rights, equating to 340,681,395 voting rights in Cellbxhealth. Shares are held in private funds managed by Conifer Management. The filing names Pershing LLC as the shareholder vehicle and lists Gregory Alexander as ultimate controlling person.

CelLBxHealth (OTCQX:ANPCY / AIM:CLBX; ADR symbol ANPCF) presented a proof-of-concept study at the 16th World ADC Conference (Nov 3-6, 2025) showing the Parsortix® platform and CellKeep slide are compatible with Roche Tissue Diagnostics' BenchMark ULTRA automated IHC workflow.

Key points: blood samples and fixed cancer cell lines were processed and sent to Roche for automated IHC analysis using HER2, TROP2, and PSMA assays; BenchMark ULTRA staining was reported compatible with CelLBxHealth's manual immunofluorescent workflow; the release highlights CTCs as dynamic biomarkers that may support ADC patient selection.

CelLBxHealth (OTCQX:ANPCF) welcomed an international expert consensus published 4 November 2025 that affirms the clinical relevance of circulating tumor cells (CTCs) and highlights the Parsortix® platform.

The consensus of 32 experts found that CTCs provide information distinct from ctDNA, 90% of respondents expect CTC testing to become routine within five years, and 40% identified Parsortix as the most promising next‑generation technology. The company also updated funding: cash runway into early 2026 and an intention to raise about £6m, with a fundraise announcement expected by early December 2025.

ANGLE plc (OTCQX:ANPCY) announced senior leadership changes on 16 October 2025: Peter Collins is appointed interim Chief Executive Officer and Klaas de Boer joins as a senior advisor to the Board. The company will be renamed CelLBxHealth plc.

Collins brings >25 years in oncology diagnostics and drug-development roles, joining in a non‑board capacity. De Boer brings >25 years of venture and finance experience and multiple board roles; the company said his experience will support a restructure and funding planned for Q4 2025. The announcement also lists investor relations contacts and advisors.

ANGLE plc (AIM:AGL / OTCQX:ANPCY) announced a strategic refocus and management change on 8 October 2025. Dr Jan Groen moves from Non-Executive Chairman to Executive Chairman to lead a revised strategy centred on CTC intelligence and accelerated commercial traction using the Parsortix platform. The company proposes a name change to CelLBxHealth plc and an AIM ticker change to CLBX, expected mid-October.

The plan emphasises proteomics and genomics applications, tighter cost control and partnerships. Cash runway is stated through to Q1 2026, and the company expects a need to raise funds in the coming months. CEO and Finance Director will transition out over the next 12 months, with contractual entitlements honoured.

ANGLE plc (OTCQX:ANPCY) presented promising data from a proof-of-concept study in glioblastoma at the 7th Advances in Circulating Tumour Cells meeting. The study, using their Parsortix® system and CellKeep™ slides, demonstrated significant capabilities in detecting circulating tumor cells (CTCs) in glioblastoma patients.

Key findings showed CTCs were detected in 60% of patients, with CTC clusters observed in 78% of CTC-positive patients. The study revealed that 73% of subjects showed extracellular vesicles (EVs), highlighting the potential for liquid biopsy in monitoring glioblastoma. Notably, the system's label-free methodology successfully detected mesenchymal phenotype CTCs, which are typically undetectable using traditional CTC technologies.

ANGLE plc (OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions, announced significant leadership changes. CEO Andrew Newland and Finance Director Ian Griffiths have agreed to step down from their positions on the Board following discussions with a major shareholder.

The current Board consists of Dr. Jan Groen as Non-executive Chairman and Dr. Joseph Eid as Non-executive Director. The company plans to expand its Board membership in the future. Both departing executives have committed to supporting an orderly transition.

ANGLE plc (OTCQX:ANPCY), a liquid biopsy company, reported its H1 2025 interim results with revenues of £0.8 million, down from £1.0 million in H1 2024. The company posted a loss of £9.3 million with cash reserves of £5.3 million extending into Q1 2026.

Key operational achievements include successful completion of contracts with Eisai and AstraZeneca, development of DNA Dual Analysis using Illumina NGS technology, and a new collaboration with Myriad Genetics. The company's Parsortix system demonstrated strong results in Eisai's Phase 2 breast cancer trial, particularly with its HER2 assay.

Despite challenging market conditions affecting revenue growth, ANGLE expects 2025 revenues to exceed £1.5 million and anticipates announcing several new high-profile collaborations in the coming months.